On March 18, Buchang Pharmaceutical announced that the company received the "Notice of Approval of Supplementary Drug Application" for Angong Niuhuang Wan approved and issued by the State Drug Administration, agreeing that the holder of the marketing authorization for Angong Niuhuang Wan has been changed from Liaoning Hancaotang to Buchang Pharmaceutical. This change will not have a significant impact on the company's current production and operation, but it will help expand the company's business, enrich its product line, and enhance its market competitiveness. The specific sales of drugs in the future may be affected by factors such as industry policies and changes in the market environment, and there is uncertainty.

21 Comments: In April 2023, Buchang Pharmaceutical announced that it plans to acquire the drug production technology of Angong Niuhuang Wan owned by Liaoning Hancaotang for 8.4 million yuan. In recent years, the sales volume and sales of Angong Niuhuang Wan industry in my country in the pharmacy market have shown a continuous growth trend. According to data, in 2023, the cumulative sales of Angong Niuhuang Pills in the pharmacy market in my country will be 5.144 billion yuan, with a five-year CAGR of 28.64%.

AstraZeneca's $1.05 billion bet ushered in a breakthrough, and the first key phase 3 clinical trial of a new drug for rare diseases was successful

On March 17, AstraZeneca announced positive results from the Phase III CALYPSO study, which aims to evaluate the efficacy and safety of eneboparatide (AZP-3601) in adult patients with chronic hypoparathyroidism (HypoPT). Eeneboparatide is a parathyroid hormone (PTH) receptor 1 agonist acquired by AstraZeneca in March 2024 when it acquired Amolyt Pharm for $1.05 billion. The disease has been included in my country's second batch of rare disease catalogs.

https://finance.eastmoney.com/a/202503173347407027.html